<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2021.08.01.21260883</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Oncology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3834-2156</contrib-id>
<name><surname>Chen</surname><given-names>Runzhe</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">&#x0023;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Jun</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">&#x0023;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fujimoto</surname><given-names>Junya</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hu</surname><given-names>Xin</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Quek</surname><given-names>Kelly</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tang</surname><given-names>Ming</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mitra</surname><given-names>Akash</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Behrens</surname><given-names>Carmen</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chow</surname><given-names>Chi-Wan</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jiang</surname><given-names>Peixin</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Little</surname><given-names>Latasha D.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gumbs</surname><given-names>Curtis</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Song</surname><given-names>Xingzhi</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Jianhua</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tan</surname><given-names>Dongfeng</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Heymach</surname><given-names>John V.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wistuba</surname><given-names>Ignacio</given-names></name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Futreal</surname><given-names>P. Andrew</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Gibbons</surname><given-names>Don L.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Byers</surname><given-names>Lauren A.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhang</surname><given-names>Jianjun</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Reuben</surname><given-names>Alexandre</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center</institution>, Houston, Texas 77030, <country>USA</country></aff>
<aff id="a2"><label>2</label><institution>Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center</institution>, Houston, Texas 77030, <country>USA</country></aff>
<aff id="a3"><label>3</label><institution>Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center</institution>, Houston, Texas 77030, <country>USA</country></aff>
<aff id="a4"><label>4</label><institution>Department of Pathology, the University of Texas MD Anderson Cancer Center</institution>, Houston, Texas 77030, <country>USA</country></aff>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="others"><label>&#x0023;</label><p>co-first authors</p></fn>
<corresp id="cor1"><label>&#x002A;</label>Correspondence: <email>dlgibbon@mdanderson.org</email> (D.L.G.), <email>lbyers@mdanderson.org</email> (L.A.B.), <email>jzhang20@mdanderson.org</email> (J.J.Z.), <email>areuben@mdanderson.org</email> (A.R.)</corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2021</year>
</pub-date>
<elocation-id>2021.08.01.21260883</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>8</month>
<year>2021</year>
</date>
<date date-type="rev-recd">
<day>01</day>
<month>8</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>8</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2021, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="21260883.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<sec>
<title>Background</title>
<p>Lung cancer is the leading cause of cancer death, partially owing to its extensive heterogeneity. The analysis of intertumor heterogeneity has been limited by an inability to concurrently obtain tissue from synchronous metastases unaltered by multiple prior lines of therapy.</p></sec>
<sec>
<title>Methods</title>
<p>In order to study the relationship between genomic, epigenomic and T cell repertoire heterogeneity in a rare autopsy case from a young female never-smoker with late-stage lung adenocarcinoma (LUAD), we did whole-exome sequencing (WES), DNA methylation and T-cell receptor (TCR) sequencing to characterize the immunogenomic landscape of one primary and 19 synchronous metastatic tumors.</p></sec>
<sec>
<title>Results</title>
<p>We observed heterogeneous mutation, methylation, and T cell patterns across distinct metastases including a set of prevalent T cell clonotypes which were completely excluded from left-side thoracic tumors. Though a limited number of predicted neoantigens were shared, these were associated with homology of the T cell repertoire across metastases. Lastly, ratio of methylated neoantigen coding mutations was negatively associated with T-cell density, richness and clonality, suggesting neoantigen methylation may partially drive immunosuppression.</p></sec>
<sec>
<title>Conclusions</title>
<p>Our study demonstrates heterogeneous genomic and T cell profiles across synchronous metastases and how restriction of unique T cell clonotypes within an individual may differentially shape the genomic and epigenomic landscapes of synchronous lung metastases.</p></sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>lung adenocarcinoma</kwd>
<kwd>intertumor heterogeneity</kwd>
<kwd>genomic</kwd>
<kwd>T cell repertoire</kwd>
</kwd-group>
<counts>
<page-count count="28"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>L.A.B. serves on advisory committees for AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar SA, Sierra Oncology, Merck, Bristol Myers Squibb, Genentech, and Pfizer and has research support from AbbVie, AstraZeneca, GenMab, Sierra Oncology and Tolero Pharmaceuticals. I.W. reports grants and personal fees from Genentech/Roche, Bayer, Bristol-Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Merck, and Guardant Health; personal fees from GlaxoSmithKline and MSD; grants from Oncoplex, DepArray, Adaptive, Adaptimmune, EMD Serono, Takeda, Amgen, Karus, Johnson &amp; Johnson, Iovance, 4D, Novartis, Oncocyte and Akoya. J.J.Z. reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed and Innovent outside the submitted work. J.V.H. reports honorariums from AstraZeneca, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche and Leads Biolabs. A.R. serves on the Scientific Advisory Board and has received honoraria from Adaptive Biotechnologies. The other authors declare no competing interests.</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>This work was supported by Conquer Cancer Foundation ASCO Young Investigator Award, MD Anderson Physician Scientist Award, Cancer Prevention &amp; Research Institute of Texas (CPRIT) Multiple Investigator Award, TJ Martell Foundation, NIH/NCI R01-CA207295, NIH/NCI U01-CA213273 and Department of Defense (LC170171). A.R. is supported by the Exon 20 Group, Rexanna's Foundation for Fighting Lung Cancer, the Waun Ki Hong Lung Cancer Research Fund, MD Anderson's Lung Cancer Moon Shot and the University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer Center.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>Collection and use of patient samples were approved by the Institutional Review Board of the University of Texas MD Anderson Cancer Center.</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Background</title>
<p>Lung cancer is the leading cause of cancer death, partially owing to its extensive heterogeneity [<xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c2">2</xref>]. It has been proposed that this extensive heterogeneity results from successive clonal expansion and selection of the fittest clones influenced by genomic accumulation and somatic epigenetic alterations [<xref ref-type="bibr" rid="c3">3</xref>&#x2013;<xref ref-type="bibr" rid="c6">6</xref>]. However, tumor evolution may also be shaped by pressure from the immune system, which can prune the most immunogenic branches of the tumor [<xref ref-type="bibr" rid="c7">7</xref>].</p>
<p>T cells play a crucial role in preventing cancer development through antigen-specific detection and destruction of malignant cells, though evolving tumors can eventually escape immune surveillance through a process termed immunoediting [<xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c8">8</xref>&#x2013;<xref ref-type="bibr" rid="c11">11</xref>]. Few studies have addressed the impact of the T cell repertoire in shaping metastatic heterogeneity [<xref ref-type="bibr" rid="c12">12</xref>&#x2013;<xref ref-type="bibr" rid="c14">14</xref>] with most work to date evaluating longitudinal changes spanning multiple timepoints and therapies. Though these studies offer crucial insights, they do not allow the evaluation of intrinsic intertumor heterogeneity in absence of selective pressure from therapy. Furthermore, to date, the analysis of intertumor heterogeneity has been limited by an inability to concurrently obtain tissue from synchronous metastases unaltered by multiple prior lines of therapy [<xref ref-type="bibr" rid="c15">15</xref>&#x2013;<xref ref-type="bibr" rid="c17">17</xref>].</p>
<p>Here, we sought to study the relationship between genomic, epigenomic and T cell repertoire heterogeneity in a rare autopsy case from a female never-smoker in her early 30s with late-stage lung adenocarcinoma (LUAD) with more than 20 synchronous metastases. We observed heterogeneous mutation, methylation, and T cell patterns across distinct metastases including a set of prevalent T cell clonotypes which were completely excluded from left-side thoracic tumors. Our work further highlights neoantigen methylation as a potential mechanism driving immunosuppression and some of the hurdles facing the treatment of late-stage lung cancer.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2a">
<title>Human subject research</title>
<p>We collected 20 tumor samples and one normal GI sample at autopsy. Collection and use of patient samples were approved by the Institutional Review Board of the University of Texas MD Anderson Cancer Center. Clinical information is presented in <bold>Supplementary Table 1</bold>.</p>
</sec>
<sec id="s2b">
<title>Sample collection</title>
<p>DNA of collected samples was isolated from FFPE tissues using the AllPrep DNA/RNA FFPE Kit (Qiagen, Hilden, Germany). Hematoxylin and eosin (H&#x0026;E) slides of each case were reviewed by experienced lung cancer pathologists under the microscope to assess the percentage of pre-/micro-invasive neoplastic lesions and tumor tissues versus normal tissues. Tumor cell viability was also assessed by examining the presence of necrosis in the tissues. Only samples with enough viable tumor cells were selected for WES, methylation and immunoSEQ.</p>
</sec>
<sec id="s2c">
<title>DNA preparation</title>
<p>Unstained tissue sections (10&#x03BC;m thick) were deparaffinized in xylene and 100&#x0025; ethanol (twice in each for 10 minutes). The macrodissected tumor areas of the deparaffinized tissues were placed into a 1.5 mL collection tubes for DNA extraction. The tissue was next suspended with Buffer PKD and Proteinase K from the Allprep FFPE kit. After incubating at 56 &#x00B0;C for 15 min then on ice for 5 min, the mixed solution was centrifuged for 15 minutes at 20,000 x g. Finally, the DNA samples were quantified by Nano Drop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The fragmentation sizes were evaluated by the Agilent 2200 Tape Station system using the Genomic DNA Screen Tape Assay (Agilent Technologies, Santa Clara, CA, USA).</p>
</sec>
<sec id="s2d">
<title>Whole-exome sequencing</title>
<p>Exome capture was performed on 500ng of genomic DNA per sample based on KAPA library prep (Kapa Biosystems) using the Agilent SureSelect Human All Exon V4 kit according to the manufacturer&#x2019;s instructions and paired-end multiplex sequencing was performed on the Illumina HiSeq 2000 sequencing platform. The average sequencing depth was 178x (ranging from 63x to 225x, standard deviation &#x002B;/- 31).</p>
</sec>
<sec id="s2e">
<title>Mutation calling</title>
<p>Tumor contents and major/minor copy number changes were estimated by Sequenza (v2.1.2) [<xref ref-type="bibr" rid="c18">18</xref>]. To control those FFPE caused artifact contaminations, somatic single nucleotide variants (SNVs) was first called using MuTect version 1.1.4 [<xref ref-type="bibr" rid="c19">19</xref>], VarScan 2 [<xref ref-type="bibr" rid="c20">20</xref>] and Strelka2 [<xref ref-type="bibr" rid="c21">21</xref>] with default setting, respectively. Then, the following filtering criteria were applied to each callers: 1) sequencing depth &#x2265;20&#x00D7; in tumor DNA and &#x2265;10&#x00D7; in germline DNA; and 2) variant allele frequency (VAF) &#x2265; 0.02 in tumor DNA and &#x003C; 0.01 in germline DNA; and 3) the total number of reads supporting the variant calls is &#x2265;4; and 4) variant frequency is &#x003C; 0.01 in ESP6500, 1000 genome and EXAC databases; Those mutations called by Mutect with a LOD score&#x003C;10 was further filtered out. Those mutations called by Strelka with a quality score below 35 was also filtered out. Finally, only those mutations were kept if called by any of the two tools and rescued if any were rejected but shared by at least two tumors. Identified missense mutations were manually reviewed using the Integrative Genomics Viewer version 2.3.61 [<xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c23">23</xref>].</p>
</sec>
<sec id="s2f">
<title>Phylogenetic analysis</title>
<p>Ancestors were germ line DNA assuming with no mutations. The phylogenetic tree was generated as described [<xref ref-type="bibr" rid="c24">24</xref>]. A binary presence/absence matrix of all somatic mutations detected was used as input for R package phangorn version 2.0.2 [<xref ref-type="bibr" rid="c25">25</xref>].</p>
</sec>
<sec id="s2g">
<title>Neoantigen predictions</title>
<p>Nonsynonymous mutations were identified from WES profiling and the binding affinity with patient-restricted MHC Class I molecules of all possible 9- and 10-mer peptides spanning the nonsynonymous mutations was evaluated with the NetMHC3.4 algorithm based on HLA-A, HLA-B, and HLA-C alleles of each patient [<xref ref-type="bibr" rid="c26">26</xref>&#x2013;<xref ref-type="bibr" rid="c28">28</xref>]. Candidate peptides were considered as HLA binders when IC50&#x003C;500 nM with high affinity binders presenting IC50&#x003C;50 nM.</p>
</sec>
<sec id="s2h">
<title>DNA methylation profiling and tumor&#x2013;immune microenvironment deconvolution</title>
<p>Genomic DNA (approximately 500 ng) was bisulfite converted using EZ DNA Methylation Kit (Zymo Research Corp. Irvine, CA, USA) following the manufacturer&#x2019;s protocol. Bisulfite converted DNA materials were then processed and hybridized to the Infinium Human Methylation 450k arrays (Illumina, San Diego, CA, USA) according to manufacturer&#x2019;s recommendation. Preprocessing and initial quality assessments of the raw data were examined using the following R packages. Subset-quantile within-array normalization (SWAN) [<xref ref-type="bibr" rid="c29">29</xref>] was used to normalize raw methylation values. IlluminaHumanMethylation450k.db annotation package was used to annotate the CpG probes location. Before any genomics and statistical analyses were conducted, we normalized and inspected the methylation data for the presence of substantial confounding batch effects. Cellular deconvolution analyses were carried out using estimated cellular fractions using MethylCIBERSORT [<xref ref-type="bibr" rid="c30">30</xref>].</p>
</sec>
<sec id="s2i">
<title>TCR&#x03B2; sequencing and comparison parameters</title>
<p>Immunosequencing of the CDR3 regions of human TCR&#x03B2; chains was performed using the protocol of immunoSEQ (Adaptive Biotechnologies, hsTCR&#x03B2; Kit) [<xref ref-type="bibr" rid="c31">31</xref>&#x2013;<xref ref-type="bibr" rid="c33">33</xref>]. Two sets of PCRs were performed on DNA extracted from the tissues collected. The initial PCR used a mix of multiplexed V- and J-gene primers which amplify all possible recombined receptor sequences from the DNA sample, and then a second PCR designing to add unique DNA barcodes to each PCR product was followed. After that, samples were pooled together with a negative and a positive control. The pools were then sequenced on an Illumina MiSeq platform using 150 cycle paired-end protocol and sequence-ready primers. After finish the sequencing, the raw data were transferred to Adaptive Biotechnologies and processed into a report including those passed quality-check samples and a normalized and annotated TCR&#x03B2; profile repertoire accordingly. Profile of TCR rearrangements is presented in <bold>Supplementary Data</bold>.</p>
<p>T-cell density in FFPE tissue samples was calculated by normalizing TCR-&#x03B2; template counts to the total amount of DNA usable for TCR sequencing, where the amount of usable DNA was determined by PCR-amplification and sequencing of housekeeping genes expected to be present in all nucleated cells. T-cell richness is a metric of T cell diversity, and it is calculated by on the T-cell unique rearrangements. T-cell clonality is a metric of T cell proliferation and reactivity, and it is defined as 1-Peilou&#x2019;s evenness. Clonality ranges from 0 to 1: values approaching 0 indicate a very even distribution of frequency of different clones (polyclonal), whereas values approaching 1 indicate a distinct asymmetric distribution in which a few activated clones are present at high frequencies (monoclonal). Statistical analysis was performed in R version 3.2. JI is conceptually a percentage of how many objects of two sets have in common out of how many objects they have in total. JI = (number of rearrangements in common) / (total number of rearrangements)</p>
</sec>
<sec id="s2j">
<title>Statistical Analysis</title>
<p>Graphs were generated with GraphPad Prism 8.0. Spearman&#x2019;s rank correlations were calculated to assess the association between 2 continuous variables. Kruskal-Wallis tests were used for categorical variables with more than 2 levels. P-values less than 0.05 were considered to be statistically significant.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Patient information</title>
<p>A female never-smoker in her early 30s presented to her primary care physician complaining of weakness in her upper right arm lasting for two weeks. Physical examination was unremarkable, other than grade 3 weakness in her right upper limb. Shortly after, she was hospitalized due to acute venous thromboembolism of this arm. She was started on anti-coagulants and underwent computed tomography (CT) scans of the chest, abdomen and pelvis and magnetic resonance imaging (MRI) of the brain as part of the work up. Numerous nodules were detected suggestive of extensive metastasis and a 1.9 cm left lung mass was consistent with a lung primary (<bold><xref rid="fig1" ref-type="fig">Fig. 1a-b</xref></bold>). A liver biopsy revealed the diagnosis of poorly differentiated LUAD. The patient underwent palliative radiation therapy for C5-C7 spine metastases with 10&#x00D7;30 cGy and one dose of chemotherapy with carboplatin and paclitaxel while awaiting molecular profiling results. Her condition deteriorated rapidly and she expired 13 days following her sole dose of chemotherapy. An autopsy was performed and widely disseminated metastatic carcinoma involving multiple systems and organs was observed.</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Synchronous metastatic tumors exhibit heterogeneous growth and somatic mutation and neoantigen patterns.</title>
<p><bold>)</bold> Anatomical map of representative biospecimen collection sites in the patient. <bold>b)</bold> Representative CT and MRI scans of different resected tumors: primary lung tumor, cervical lymph node enlargement, liver metastasis and C5 spine compression fracture by metastasis. <bold>c)</bold> Non-silent mutation counts in tumors. <bold>d)</bold> Fraction of shared and unique non-silent mutations across tumors.</p></caption>
<graphic xlink:href="21260883v1_fig1.tif"/>
</fig>
<p>To understand the genomic and T cell landscape of this extensively metastatic LUAD, 20 tumor samples (<bold>Supplementary Table 1</bold>) including the left lung (primary tumor, P), thyroid gland (M01), left pleural cavity (M02), left hilar lymph node (M03), left-side parietal pleura (M04), heart (M05), right lung (M06), right pleural cavity (M07), 12<sup>th</sup> thoracic vertebra (M08), gastrointestinal (GI) tract (M09), liver (M10), 4 abdominal lymph nodes (M11-14), left adrenal gland (M15), two metastases in the right kidney (M16 and M17), left and right ovaries (M18 and M19) as well as one histologically normal sample from the GI tract were collected and subjected to whole-exome sequencing (WES), DNA methylation array and T cell receptor (TCR) sequencing.</p>
</sec>
<sec id="s3b">
<title>Distinct mutational profiles are seen across primary tumor and synchronous metastases</title>
<p>Overall, 228 non-silent mutations were detected with an average of 76 per sample (range=57-98). The number of non-silent mutations varied between tumors, with only 10 shared across all 20 samples (<bold><xref rid="fig1" ref-type="fig">Fig. 1c</xref></bold>). Of these non-silent mutations, 170 (75&#x0025;) were shared by at least two tumors while 58 (25&#x0025;) were unique (<bold><xref rid="fig1" ref-type="fig">Fig. 1d</xref></bold>). When canonical cancer gene mutations were analyzed[<xref ref-type="bibr" rid="c34">34</xref>&#x2013;<xref ref-type="bibr" rid="c36">36</xref>], commonly-mutated cancer genes included TP53, CDKN2A, ASXL1 and MET in this patient (<bold>Supplementary Fig. 1a</bold>). Only TP53 mutation (chromosome 17_7578382, stop gain, spectrum G-&#x003E;C) was detected in all tumors suggesting TP53 mutation was an early genomic event, while other cancer gene mutations were later events which may have followed subclonal diversification. We also constructed a phylogenetic tree to depict the genomic heterogeneity and evolutionary trajectory of these metastatic tumors. As shown in <bold>Supplementary Fig. 1b</bold>, the phylogenetic structure varied considerably between tumors highlighting profound genomic heterogeneity within this patient. We also utilized the Jaccard index (JI), which takes into consideration the proportion of shared non-silent mutations between any two samples. The JI ranged from 0.14 to 0.82 (average=0.49) with more proximal tumors generally more genetically similar (<bold>Supplementary Fig. 1c</bold>). Homology between the primary and metastases ranged from 0.14 to 0.73 (average=0.33), with the thoracic lesions including the left pleural metastasis, left hilar lymph node and right pleural metastasis exhibiting the greatest similarity with the primary tumor. Taken together, these results reveal marked genomic heterogeneity across different metastases within the same patient.</p>
</sec>
<sec id="s3c">
<title>The T cell infiltrate in distant metastases is more dense, diverse and reactive</title>
<p>The crucial role of T cells in immunoediting led us to study the T cell repertoire to further investigate the spatial heterogeneity of T-cell responses[<xref ref-type="bibr" rid="c37">37</xref>, <xref ref-type="bibr" rid="c38">38</xref>]. T-cell density, an estimate of the fraction of T cells within a tumor, ranged from 3&#x0025; to 38&#x0025; (average=13&#x0025;, <bold><xref rid="fig2" ref-type="fig">Fig. 2a</xref></bold>), while richness, a measure of T-cell diversity, ranged from 4,168 to 23,487 unique T-cell rearrangements (average=14,344 unique rearrangements, <bold><xref rid="fig2" ref-type="fig">Fig. 2b</xref></bold>). T-cell clonality, a measure of T-cell reactivity, ranged from 0.02 to 0.05 (average=0.04, <bold><xref rid="fig2" ref-type="fig">Fig. 2c</xref></bold>). All TCR metrics were positively inter-correlated (Density <italic>vs</italic>. Richness: r=0.53, p=0.02; Density <italic>vs</italic>. Clonality: r=0.54, p=0.02; Clonality <italic>vs</italic>. Richness: r=0.54, p=0.01, <bold><xref rid="fig2" ref-type="fig">Fig. 2d</xref></bold>). Compared to prior work from our group in an early-stage LUAD cohort[<xref ref-type="bibr" rid="c39">39</xref>], lower T-cell density (p&#x003C;0.05) and clonality (p&#x003C;0.0001) and higher richness (p&#x003C;0.0001) were observed in tumors from this patient (<bold>Supplementary Fig. 2a-e</bold>).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Characterization of TCR repertoire metrics across tumors.</title>
<p>T-cell <bold>a)</bold> density, <bold>b)</bold> richness and <bold>c)</bold> clonality. <bold>d)</bold> Correlation between T-cell fraction, richness and clonality. <bold>e)</bold> Distribution of most prevalent TCR clonotype.</p></caption>
<graphic xlink:href="21260883v1_fig2.tif"/>
</fig>
<p>Tumors were then grouped anatomically. Non-thoracic tumors displayed higher T-cell density (p&#x003C;0.01), richness (p&#x003C;0.0001) and clonality (p&#x003C;0.01) than thoracic tumors (<bold>Supplementary Fig. 3a-c</bold>), perhaps owing to their anatomical location far from the primary tumor which are more likely to escape from immune surveillance[<xref ref-type="bibr" rid="c40">40</xref>, <xref ref-type="bibr" rid="c41">41</xref>]. Lymph nodes serve as sites of T cell priming, activation, and modulation, leading us to speculate that the interaction between metastatic cancer cells and T cells in lymph nodes may be distinct compared to other sites of metastases. However, no statistical differences were observed in relation to lymph node involvement (<bold>Supplementary Fig. 3d-f</bold>). Taken together, these data suggest differences in T cell response based on anatomical site, that is, T cell exclusion, suppression and a more focused T cell response in proximity to the primary tumor.</p>
</sec>
<sec id="s3d">
<title>Distinct TCR repertoire profiles are associated with left-side thoracic tumors</title>
<p>To evaluate T-cell responses in the tumors, we next focused on the most prevalent TCR clonotypes. Distinct clonotypes were detected in left-side thoracic tumors (left lung tumor, left pleural cavity and rib, left pulmonary hilar lymph node and left side parietal pleura) compared to others. Strikingly, the most prevalent clonotype in &#x201C;other&#x201D; tumors (<italic>CACRPGNEAFF</italic>) was entirely undetectable in left-side thoracic tumors (P, M02, M03 and M04) (<bold><xref rid="fig2" ref-type="fig">Fig. 2e</xref></bold>). Similar trends were also observed among the top 5 and 10 TCR clonotypes with certain clonotypes completely excluded from left side thoracic tumors (<bold>Supplementary Fig. 4a-b</bold>). These data illustrate spatial restriction even among the most prevalent T cell clonotypes across synchronous metastases.</p>
</sec>
<sec id="s3e">
<title>T-cell repertoire heterogeneity is observed across differentially growing tumors</title>
<p>To gain deeper insights into TCR heterogeneity, we assessed the overlap between T cell repertoires across different tumors. We first compared the proportion (JI) and frequency of T cell clonotypes shared between the primary tumor and metastases. In accordance with the unique T cell clonotype pattern observed in tumors from the left side thorax, proportions and frequencies of shared T cells were much more similar between the three left thoracic metastases (M02, M03 and M04) and primary tumor (P) (<bold><xref rid="fig3" ref-type="fig">Fig. 3a-c</xref></bold>). T cell repertoire heterogeneity was evident across all tumors, with an average JI value of 0.35 (ranging from 0.12 to 0.61) and more shared T cells between proximal tumors (<bold><xref rid="fig4" ref-type="fig">Fig. 4a</xref></bold>), significantly higher than in a previously published cohort of 11 multi-region localized non-small cell lung cancers[<xref ref-type="bibr" rid="c42">42</xref>] (average 0.35 <italic>vs</italic>. 0.17, p&#x003C;0.0001) (<bold>Supplementary Fig. 5</bold>). Next, we studied the proportion and frequency of shared T cell clonotypes across all 20 tumors. In total, 599 shared T-cell clones were shared across all tumors, with proportions ranging from 3.0&#x0025; to 15.4&#x0025; (average=5.39&#x0025;) and frequencies accounting for 11.9&#x0025; to 21.5&#x0025; of the T cell repertoire (average=15.96&#x0025;) (<bold>Supplementary Fig. 6a-b</bold>). Of interest, both a greater proportion (p&#x003C;0.01) and percentage (p&#x003C;0.01) of shared T cell clones were observed in thoracic tumors compared to non-thoracic tumors (<bold>Supplementary Fig. 6c-d</bold>).</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><title>T-cell repertoire heterogeneity is observed across differentially growing tumors.</title>
<p><bold>)</bold> Number of T-cell clonotypes in the primary tumor (red), metastases (blue) or shared (purple). <bold>b)</bold> Shared T-cell clonotype proportions and <bold>c)</bold> frequencies between the primary tumor and metastases.</p></caption>
<graphic xlink:href="21260883v1_fig3.tif"/>
</fig>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Evolution of synchronous metastases may be shaped by the T cell repertoire.</title>
<p><bold>)</bold> Quantification of TCR repertoire heterogeneity across tumors by Jaccard index (JI). <bold>b)</bold> Quantification of predicted neoantigen heterogeneity across tumors by JI. <bold>c)</bold> Correlation between TCR repertoire JI and predicted neoantigen JI. <bold>d)</bold> Deconvolution of immune components and T cell subpopulations by MethylCIBERSORT. <bold>e)</bold> Correlation between T-cell richness and estimated CD8<sup>&#x002B;</sup> T-cell fraction. <bold>f)</bold> Correlation between T-cell clonality and estimated CD8<sup>&#x002B;</sup> T-cell fraction.</p></caption>
<graphic xlink:href="21260883v1_fig4.tif"/>
</fig>
</sec>
<sec id="s3f">
<title>Evolution of synchronous metastases may be shaped by the T cell repertoire</title>
<p>We next performed <italic>in silico</italic> prediction of HLA-A-, -B-, and -C-presented neoantigens using NetMHC3.4[<xref ref-type="bibr" rid="c26">26</xref>&#x2013;<xref ref-type="bibr" rid="c28">28</xref>]. On average, 39 predicted neoantigens (IC50 &#x003C; 500 nmol/L) were detected per tumor, with the most (n=60) seen in the primary tumor and fewest (n=20) in the thyroid gland. Only 11 high binding affinity neoantigens were detected on average (IC50 &#x003C; 50 nmol/L) with the most (n=19) also in the primary tumor and least (n=2) in the thyroid gland (<bold><xref rid="fig5" ref-type="fig">Fig. 5a</xref></bold>). This falls within range but below the average of 53 predicted neoantigens seen in non-smokers from TCGA (<bold><xref rid="fig5" ref-type="fig">Fig. 5b</xref></bold>). We then evaluated the relationship between the T cell repertoire and predicted neoantigens. Predicted neoantigen heterogeneity was also evident, with the average JI value of 0.44 (ranging from 0.11 to 0.84, <bold><xref rid="fig4" ref-type="fig">Fig. 4b</xref></bold>), and a weak but statistically-significant positive correlation between T-cell repertoire and neoantigen homology (r=0.12, p=0.0162, <bold><xref rid="fig4" ref-type="fig">Fig. 4c</xref></bold>), which could suggest the distribution of T cells may be partially driven by their reactivity to shared neoantigens. Interestingly, ratio of methylated neoantigen coding mutations was negatively associated with T-cell density (r=-0.46, p=0.0549), richness (r=-0.55, p=0.0152) and clonality (r=-0.61, p=0.0055) (<bold><xref rid="fig5" ref-type="fig">Fig. 5c-e</xref></bold>), suggesting neoantigen methylation may contribute to immune suppression and potentially explaining the weak neoantigen associations with T cell repertoire homology.</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Methylated neoantigen burden is inversely correlated with T cell repertoire metrics.</title>
<p><bold>)</bold> Total number of predicted neoantigens across tumors. <bold>b)</bold> Comparison of predicted neoantigens between TCGA cohort and tumors in our study. Correlation between ratio of methylated neoantigen coding mutations and T-cell <bold>c)</bold> density, <bold>d)</bold> richness and <bold>e)</bold> clonality.</p></caption>
<graphic xlink:href="21260883v1_fig5.tif"/>
</fig>
<p>In order to classify the T cell subsets infiltrating the tumor, we next performed cellular deconvolution analyses using MethylCIBERSORT (<bold><xref rid="fig4" ref-type="fig">Fig. 4d</xref></bold>)[<xref ref-type="bibr" rid="c30">30</xref>]. Relative CD8<sup>&#x002B;</sup> T cell fraction but not CD4<sup>&#x002B;</sup> and other immune subsets was proportional to richness (r=0.75, p=0.0002) and clonality (r=0.43, p=0.063) (<bold><xref rid="fig4" ref-type="fig">Fig. 4e-f</xref></bold>). Furthermore, CD8 to Treg ratio, which correlates with a more favorable outcome in cancer[<xref ref-type="bibr" rid="c43">43</xref>, <xref ref-type="bibr" rid="c44">44</xref>], was proportional to T-cell richness (r=0.68, p=0.0012) and clonality (r=0.64, p=0.032) (<bold>Supplementary Fig. 7a-b</bold>). A negative correlation between CD8<sup>&#x002B;</sup> T cell fraction and methylated neoantigen coding mutations was also observed (r=-0.48, p=0.0391, <bold><xref rid="fig5" ref-type="fig">Fig. 5e</xref></bold>). These results highlight the greater proliferative potential of CD8<sup>&#x002B;</sup> T cells and suggest T cell reactivity and diversity may be mainly driven by the clonal expansion of CD8<sup>&#x002B;</sup> T cells at the patient level, as previously suggested by our group and others in a large cohort of early-stage non-small cell lung cancers[<xref ref-type="bibr" rid="c45">45</xref>]. Overall, our findings suggest that the evolution of synchronous metastases may be shaped by the T cell response including in absence of prior therapy.</p>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>Metastasis is an evolutionary process shaped by the dynamic interactions between tumor cells and host factors including immune surveillance [<xref ref-type="bibr" rid="c46">46</xref>]. T cells play a pivotal role in mediating this process by recognizing antigens presented on MHC molecules at the surface of tumors and carrying out cytotoxic responses against tumor cells harboring their cognate antigens [<xref ref-type="bibr" rid="c47">47</xref>]. Accordingly, much importance has been attributed to T cell infiltration in many solid tumors, with more T cells generally associated with a better prognosis [<xref ref-type="bibr" rid="c37">37</xref>, <xref ref-type="bibr" rid="c48">48</xref>, <xref ref-type="bibr" rid="c49">49</xref>]. However, recent studies have highlighted the impact of intratumor heterogeneity and bystander T cells [<xref ref-type="bibr" rid="c50">50</xref>&#x2013;<xref ref-type="bibr" rid="c52">52</xref>], and suggested that only &#x223C;10&#x0025; of tumor-infiltrating lymphocytes are capable of recognizing antigens presented by the tumor they have infiltrated [<xref ref-type="bibr" rid="c53">53</xref>], prompting deeper investigations into the T cell repertoire. Our understanding of the role of genomic and immune heterogeneity in lung cancer has evolved in recent years, thanks to investigations by our group and others into differences between regions of individual tumors, synchronous metastases and between primary and metastatic tumors [<xref ref-type="bibr" rid="c54">54</xref>&#x2013;<xref ref-type="bibr" rid="c58">58</xref>] highlighting potential spatial and temporal factors influencing clinical outcomes [<xref ref-type="bibr" rid="c59">59</xref>, <xref ref-type="bibr" rid="c60">60</xref>]. Here, we assess the characteristics of the T cell repertoire in a treatment-na&#x00EF;ve non-smoking patient with synchronous lung metastases and depict the interplay between the primary tumor and synchronous metastases [<xref ref-type="bibr" rid="c11">11</xref>, <xref ref-type="bibr" rid="c55">55</xref>, <xref ref-type="bibr" rid="c61">61</xref>], revealing extensive immunogenomic intertumor heterogeneity across primary and metastatic sites.</p>
<p>In our study, clonal <italic>TP53</italic> mutations were detectable in all tumors, suggestive of an early genomic event, in line with prior reports [<xref ref-type="bibr" rid="c24">24</xref>, <xref ref-type="bibr" rid="c62">62</xref>]. Interestingly, a higher overlap in somatic mutations was observed across proximal tumors suggesting they are more genetically similar, potentially due to metastatic seeding from the primary tumor [<xref ref-type="bibr" rid="c63">63</xref>, <xref ref-type="bibr" rid="c64">64</xref>]. Though our study focused on a single patient, the overlap in mutational burden observed between synchronous metastases is in line with previous reports in lung [<xref ref-type="bibr" rid="c58">58</xref>], melanoma [<xref ref-type="bibr" rid="c65">65</xref>], kidney [<xref ref-type="bibr" rid="c66">66</xref>] and colon cancer [<xref ref-type="bibr" rid="c67">67</xref>]. Considering the role of somatic mutations in triggering T cell responses through the generation of neoantigens, this overlap suggests these somatic mutations may serve as potential therapeutic targets for vaccination or T cell engineering through targeting of unifying antigens present across all synchronous tumors. This is supported by the modest but significant correlation between shared mutations and shared TCRs though additional studies are needed to confirm these hypotheses.</p>
<p>We observed lower T cell repertoire heterogeneity across synchronous metastases in our study than in our prior work assessing multi-region ITH in localized LUAD [<xref ref-type="bibr" rid="c55">55</xref>]. This difference could highlight the distinct resistance mechanisms at play in accelerated progression in our study versus more gradual progression in early-stage LUAD which may have allowed for divergent genomic evolution and immune editing over decades. This is reinforced by the absolute restriction of certain T cell clonotypes to metastases surrounding the primary tumor, which could be reflective of the distinct antigenic environments established in distal tumors. Unfortunately, our lack of deep immune phenotyping data precludes our ability to further investigate the role the distinct immune microenvironments, including chemokine gradients and receptors, may have played in establishing these vastly distinct T cell microenvironments. However, the presence of shared T cell clonotypes could also be indicative of common responses against unifying antigens displayed across synchronous metastases.</p>
<p>Aberrant methylation is involved in tumorigenesis in a variety of cancers [<xref ref-type="bibr" rid="c68">68</xref>, <xref ref-type="bibr" rid="c69">69</xref>] and could affect immune surveillance directly by regulating the expression of immune-related genes and/or potential neoantigens[<xref ref-type="bibr" rid="c70">70</xref>]. DNA methylation-induced silencing of genes that encode tumor associated antigens form a complex gene-regulatory network for suppressing anti-tumor immune responses and therefore facilitating immune evasion [<xref ref-type="bibr" rid="c71">71</xref>]. Interestingly, in the current study, ratio of methylated neoantigen coding mutations was negatively associated with T-cell density, richness and clonality, even at the individual tumor level. One could therefore hypothesize that therapeutic agents modulating methylation could potentially reprogram the immune microenvironment and could exhibit some potential in treating these tumors.</p>
<p>Our study does exhibit certain limitations, including its focus on a single patient. However, analysis of several synchronous tumor sites from a single patient with advanced disease in absence of heavy pre-treatment is rarely possible, mainly due to the lack of clinical indication. Unfortunately, deeper analysis of underlying mechanisms, immune cells and soluble factors influencing T cell trafficking and heterogeneity remain unclear due to the archival nature of these samples and will require further investigation. Despite these limitations, our study provides important evidence of differential tumor-immune responses co-existing in metastases within the same individual, related not only to molecular alterations. As a result, our findings may also partially explain the challenge of treating late-stage lung cancer due to the heterogeneity of metastases. Additional genomic, transcriptomic and immune studies in patients with synchronous metastases could help shed light on these and other mechanisms at play and provide therapeutic insights into late-stage non-small cell lung cancer. Lastly, our findings emphasize the need to obtain multiple biopsies when feasible in patients with multiple synchronous lung tumors as has been suggested in metastatic melanoma, even in absence of selective pressure from therapy. Concurrent analysis of multiple tumors from the same patient could help identify unifying antigens and mechanisms capable of prolonging survival in patients with metastatic lung cancer [<xref ref-type="bibr" rid="c65">65</xref>].</p>
</sec>
<sec id="s5">
<title>Conclusion</title>
<p>In summary, in this study, we present the immunogenomic landscape of one primary tumor and 19 synchronous metastases from a minimally-pretreated young female never-smoker with late-stage LUAD. Fewer less diverse and reactive T cells infiltrated the metastases nearest to the primary tumor, and a set of prevalent T cell clonotypes were excluded from left-side thoracic tumors further suggesting immune escape near the primary site. Furthermore, shared predicted neoantigens were associated with homology of the T cell repertoire across metastases. Lastly, ratio of methylated neoantigen coding mutations was negatively associated with T-cell density, richness and clonality, suggesting neoantigen methylation may partially drive immunosuppression. Our study demonstrates heterogeneous genomic and T cell profiles across synchronous metastases and how restriction of unique T cell clonotypes within an individual may differentially shape the genomic and epigenomic landscapes of synchronous lung metastases.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material>
<label>Supplementary figures</label>
<media xlink:href="supplements/260883_file04.docx" />
</supplementary-material>
<supplementary-material>
<label>Supplementary data</label>
<media xlink:href="supplements/260883_file05.xlsx" />
</supplementary-material>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>Data are available from the authors upon reasonable request</p>
</sec>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>CT</term>
<def><p>computed tomography</p></def>
</def-item>
<def-item>
<term>H&#x0026;E</term>
<def><p>hematoxylin and eosin</p></def>
</def-item>
<def-item>
<term>JI</term>
<def><p>Jaccard index</p></def>
</def-item>
<def-item>
<term>LUAD</term>
<def><p>lung adenocarcinoma</p></def>
</def-item>
<def-item>
<term>MRI</term>
<def><p>magnetic resonance imaging</p></def>
</def-item>
<def-item>
<term>SNVs</term>
<def><p>single nucleotide variants</p></def>
</def-item>
<def-item>
<term>SWAN</term>
<def><p>subset-quantile within-array normalization</p></def>
</def-item>
<def-item>
<term>TCR</term>
<def><p>T cell receptor</p></def>
</def-item>
<def-item>
<term>WES</term>
<def><p>whole-exome sequencing</p></def>
</def-item>
<def-item>
<term>VAF</term>
<def><p>variant allele frequency</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Tan</surname> <given-names>WL</given-names></string-name>, <string-name><surname>Jain</surname> <given-names>A</given-names></string-name>, <string-name><surname>Takano</surname> <given-names>A</given-names></string-name>, <string-name><surname>Newell</surname> <given-names>EW</given-names></string-name>, <string-name><surname>Iyer</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>WT</given-names></string-name>, <etal>et al.</etal> <article-title>Novel therapeutic targets on the horizon for lung cancer</article-title>. <source>The Lancet Oncology</source>. <year>2016</year>; <volume>17</volume>:<fpage>e347</fpage>&#x2013;<lpage>e62</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Negrao</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Quek</surname> <given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sepesi</surname> <given-names>B.</given-names></string-name> <article-title>TRACERx: Tracking tumor evolution to impact the course of lung cancer</article-title>. <source>The Journal of thoracic and cardiovascular surgery</source>. <year>2018</year>; <volume>155</volume>:<fpage>1199</fpage>&#x2013;<lpage>202</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Nowell</surname> <given-names>PC</given-names></string-name>. <article-title>The clonal evolution of tumor cell populations</article-title>. <source>Science</source>. <year>1976</year>; <volume>194</volume>:<fpage>23</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Valastyan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Weinberg</surname> <given-names>RA</given-names></string-name>. <article-title>Tumor metastasis: molecular insights and evolving paradigms</article-title>. <source>Cell</source>. <year>2011</year>; <volume>147</volume>:<fpage>275</fpage>&#x2013;<lpage>92</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Yates</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Campbell</surname> <given-names>PJ</given-names></string-name>. <article-title>Evolution of the cancer genome</article-title>. <source>Nat Rev Genet</source>. <year>2012</year>; <volume>13</volume>:<fpage>795</fpage>&#x2013;<lpage>806</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Quek</surname> <given-names>K</given-names></string-name>, <string-name><surname>Li</surname> <given-names>J</given-names></string-name>, <string-name><surname>Estecio</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Fujimoto</surname> <given-names>J</given-names></string-name>, <string-name><surname>Roarty</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>DNA methylation intratumor heterogeneity in localized lung adenocarcinomas</article-title>. <source>Oncotarget</source>. <year>2017</year>; <volume>8</volume>:<fpage>21994</fpage>&#x2013;<lpage>2002</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Galon</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bruni</surname> <given-names>D.</given-names></string-name> <article-title>Tumor Immunology and Tumor Evolution: Intertwined Histories</article-title>. <source>Immunity</source>. <year>2020</year>; <volume>52</volume>:<fpage>55</fpage>&#x2013;<lpage>81</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>De Visser</surname> <given-names>KE</given-names></string-name>, <string-name><surname>Eichten</surname> <given-names>A</given-names></string-name>, <string-name><surname>Coussens</surname> <given-names>LM</given-names></string-name>. <article-title>Paradoxical roles of the immune system during cancer development</article-title>. <source>Nature reviews cancer</source>. <year>2006</year>; <volume>6</volume>:<fpage>24</fpage>&#x2013;<lpage>37</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Schreiber</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Old</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Smyth</surname> <given-names>MJ</given-names></string-name>. <article-title>Cancer immunoediting: integrating immunity&#x2019;s roles in cancer suppression and promotion</article-title>. <source>Science (New York, NY)</source>. <year>2011</year>; <volume>331</volume>:<fpage>1565</fpage>&#x2013;<lpage>70</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Dunn</surname> <given-names>GP</given-names></string-name>, <string-name><surname>Old</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Schreiber</surname> <given-names>RD</given-names></string-name>. <article-title>The three Es of cancer immunoediting</article-title>. <source>Annual review of immunology</source>. <year>2004</year>; <volume>22</volume>:<fpage>329</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>McGranahan</surname> <given-names>N</given-names></string-name>, <string-name><surname>Furness</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Rosenthal</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ramskov</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lyngaa</surname> <given-names>R</given-names></string-name>, <string-name><surname>Saini</surname> <given-names>SK</given-names></string-name>, <etal>et al.</etal> <article-title>Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade</article-title>. <source>Science</source>. <year>2016</year>; <volume>351</volume>:<fpage>1463</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Angelova</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mlecnik</surname> <given-names>B</given-names></string-name>, <string-name><surname>Vasaturo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bindea</surname> <given-names>G</given-names></string-name>, <string-name><surname>Fredriksen</surname> <given-names>T</given-names></string-name>, <string-name><surname>Lafontaine</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>Evolution of Metastases in Space and Time under Immune Selection</article-title>. <source>Cell</source>. <year>2018</year>; <volume>175</volume>:<fpage>751</fpage>&#x2013;<lpage>65</lpage>.e16.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname> <given-names>AW</given-names></string-name>, <string-name><surname>McPherson</surname> <given-names>A</given-names></string-name>, <string-name><surname>Milne</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kroeger</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Hamilton</surname> <given-names>PT</given-names></string-name>, <string-name><surname>Miranda</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer</article-title>. <source>Cell</source>. <year>2018</year>; <volume>173</volume>:<fpage>1755</fpage>&#x2013;<lpage>69</lpage>.e22.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Jimenez-Sanchez</surname> <given-names>A</given-names></string-name>, <string-name><surname>Memon</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pourpe</surname> <given-names>S</given-names></string-name>, <string-name><surname>Veeraraghavan</surname> <given-names>H</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Vargas</surname> <given-names>HA</given-names></string-name>, <etal>et al.</etal> <article-title>Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient</article-title>. <source>Cell</source>. <year>2017</year>; <volume>170</volume>:<fpage>927</fpage>&#x2013;<lpage>38</lpage>.e20.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Shain</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Bagger</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Yu</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Vemula</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>The genetic evolution of metastatic uveal melanoma</article-title>. <source>Nature genetics</source>. <year>2019</year>; <volume>51</volume>:<fpage>1123</fpage>&#x2013;<lpage>30</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Menzies</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Yeh</surname> <given-names>I</given-names></string-name>, <string-name><surname>Botton</surname> <given-names>T</given-names></string-name>, <string-name><surname>Bastian</surname> <given-names>BC</given-names></string-name>, <string-name><surname>Scolyer</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Long</surname> <given-names>GV</given-names></string-name>. <article-title>Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion</article-title>. <source>Pigment cell &#x0026; melanoma research</source>. <year>2015</year>; <volume>28</volume>:<fpage>607</fpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Sanborn</surname> <given-names>JZ</given-names></string-name>, <string-name><surname>Chung</surname> <given-names>J</given-names></string-name>, <string-name><surname>Purdom</surname> <given-names>E</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Kakavand</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wilmott</surname> <given-names>JS</given-names></string-name>, <etal>et al.</etal> <article-title>Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>2015</year>; <volume>112</volume>:<fpage>10995</fpage>&#x2013;<lpage>1000</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Favero</surname> <given-names>F</given-names></string-name>, <string-name><surname>Joshi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Marquard</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Birkbak</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Krzystanek</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Q</given-names></string-name>, <etal>et al.</etal> <article-title>Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data</article-title>. <source>Ann Oncol</source>. <year>2015</year>; <volume>26</volume>:<fpage>64</fpage>&#x2013;<lpage>70</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Cibulskis</surname> <given-names>K</given-names></string-name>, <string-name><surname>Lawrence</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Carter</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Sivachenko</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jaffe</surname> <given-names>D</given-names></string-name>, <string-name><surname>Sougnez</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>. <source>Nature biotechnology</source>. <year>2013</year>; <volume>31</volume>:<fpage>213</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Koboldt</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Larson</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>D</given-names></string-name>, <string-name><surname>McLellan</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing</article-title>. <source>Genome research</source>. <year>2012</year>; <volume>22</volume>:<fpage>568</fpage>&#x2013;<lpage>76</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname> <given-names>S</given-names></string-name>, <string-name><surname>Scheffler</surname> <given-names>K</given-names></string-name>, <string-name><surname>Halpern</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Bekritsky</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Noh</surname> <given-names>E</given-names></string-name>, <string-name><surname>Kallberg</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Strelka2: fast and accurate calling of germline and somatic variants</article-title>. <source>Nature methods</source>. <year>2018</year>; <volume>15</volume>:<fpage>591</fpage>&#x2013;<lpage>4</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Robinson</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Thorvaldsdottir</surname> <given-names>H</given-names></string-name>, <string-name><surname>Winckler</surname> <given-names>W</given-names></string-name>, <string-name><surname>Guttman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lander</surname> <given-names>ES</given-names></string-name>, <string-name><surname>Getz</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title>Integrative genomics viewer</article-title>. <source>Nature biotechnology</source>. <year>2011</year>; <volume>29</volume>:<fpage>24</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Thorvaldsdottir</surname> <given-names>H</given-names></string-name>, <string-name><surname>Robinson</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Mesirov</surname> <given-names>JP</given-names></string-name>. <article-title>Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration</article-title>. <source>Briefings in bioinformatics</source>. <year>2013</year>; <volume>14</volume>:<fpage>178</fpage>&#x2013;<lpage>92</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Jamal-Hanjani</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wilson</surname> <given-names>GA</given-names></string-name>, <string-name><surname>McGranahan</surname> <given-names>N</given-names></string-name>, <string-name><surname>Birkbak</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Watkins</surname> <given-names>TBK</given-names></string-name>, <string-name><surname>Veeriah</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>Tracking the Evolution of Non-Small-Cell Lung Cancer</article-title>. <source>The New England journal of medicine</source>. <year>2017</year>; <volume>376</volume>:<fpage>2109</fpage>&#x2013;<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Schliep</surname> <given-names>KP</given-names></string-name>. <article-title>phangorn: phylogenetic analysis in R</article-title>. <source>Bioinformatics (Oxford, England)</source>. <year>2011</year>; <volume>27</volume>:<fpage>592</fpage>&#x2013;<lpage>3</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Lundegaard</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lamberth</surname> <given-names>K</given-names></string-name>, <string-name><surname>Harndahl</surname> <given-names>M</given-names></string-name>, <string-name><surname>Buus</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lund</surname> <given-names>O</given-names></string-name>, <string-name><surname>Nielsen</surname> <given-names>M.</given-names></string-name> <article-title>NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11</article-title>. <source>Nucleic acids research</source>. <year>2008</year>; <volume>36</volume>:<fpage>W509</fpage>&#x2013;<lpage>12</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Lundegaard</surname> <given-names>C</given-names></string-name>, <string-name><surname>Lund</surname> <given-names>O</given-names></string-name>, <string-name><surname>Nielsen</surname> <given-names>M.</given-names></string-name> <article-title>Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers</article-title>. <source>Bioinformatics (Oxford, England)</source>. <year>2008</year>; <volume>24</volume>:<fpage>1397</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Nielsen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lundegaard</surname> <given-names>C</given-names></string-name>, <string-name><surname>Blicher</surname> <given-names>T</given-names></string-name>, <string-name><surname>Lamberth</surname> <given-names>K</given-names></string-name>, <string-name><surname>Harndahl</surname> <given-names>M</given-names></string-name>, <string-name><surname>Justesen</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence</article-title>. <source>PloS one</source>. <year>2007</year>; <volume>2</volume>:<fpage>e796</fpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Turker</surname> <given-names>MS</given-names></string-name>. <article-title>The establishment and maintenance of DNA methylation patterns in mouse somatic cells</article-title>. <source>Seminars in cancer biology</source>. <year>1999</year>; <volume>9</volume>:<fpage>329</fpage>&#x2013;<lpage>37</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Chakravarthy</surname> <given-names>A</given-names></string-name>, <string-name><surname>Furness</surname> <given-names>A</given-names></string-name>, <string-name><surname>Joshi</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ghorani</surname> <given-names>E</given-names></string-name>, <string-name><surname>Ford</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ward</surname> <given-names>MJ</given-names></string-name>, <etal>et al.</etal> <article-title>Pan-cancer deconvolution of tumour composition using DNA methylation</article-title>. <source>Nature communications</source>. <year>2018</year>; <volume>9</volume>:<fpage>3220</fpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Robins</surname> <given-names>HS</given-names></string-name>, <string-name><surname>Campregher</surname> <given-names>PV</given-names></string-name>, <string-name><surname>Srivastava</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Wacher</surname> <given-names>A</given-names></string-name>, <string-name><surname>Turtle</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Kahsai</surname> <given-names>O</given-names></string-name>, <etal>et al.</etal> <article-title>Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells</article-title>. <source>Blood</source>. <year>2009</year>; <volume>114</volume>:<fpage>4099</fpage>&#x2013;<lpage>107</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Carlson</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Emerson</surname> <given-names>RO</given-names></string-name>, <string-name><surname>Sherwood</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Desmarais</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chung</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Parsons</surname> <given-names>JM</given-names></string-name>, <etal>et al.</etal> <article-title>Using synthetic templates to design an unbiased multiplex PCR assay</article-title>. <source>Nature communications</source>. <year>2013</year>; <volume>4</volume>:<fpage>2680</fpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Robins</surname> <given-names>H</given-names></string-name>, <string-name><surname>Desmarais</surname> <given-names>C</given-names></string-name>, <string-name><surname>Matthis</surname> <given-names>J</given-names></string-name>, <string-name><surname>Livingston</surname> <given-names>R</given-names></string-name>, <string-name><surname>Andriesen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Reijonen</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title>Ultra-sensitive detection of rare T cell clones</article-title>. <source>Journal of immunological methods</source>. <year>2012</year>; <volume>375</volume>:<fpage>14</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Ding</surname> <given-names>L</given-names></string-name>, <string-name><surname>Getz</surname> <given-names>G</given-names></string-name>, <string-name><surname>Wheeler</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Mardis</surname> <given-names>ER</given-names></string-name>, <string-name><surname>McLellan</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Cibulskis</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>Somatic mutations affect key pathways in lung adenocarcinoma</article-title>. <source>Nature</source>. <year>2008</year>; <volume>455</volume>:<fpage>1069</fpage>&#x2013;<lpage>75</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Imielinski</surname> <given-names>M</given-names></string-name>, <string-name><surname>Berger</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Hammerman</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Hernandez</surname> <given-names>B</given-names></string-name>, <string-name><surname>Pugh</surname> <given-names>TJ</given-names></string-name>, <string-name><surname>Hodis</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing</article-title>. <source>Cell</source>. <year>2012</year>; <volume>150</volume>:<fpage>1107</fpage>&#x2013;<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Govindan</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ding</surname> <given-names>L</given-names></string-name>, <string-name><surname>Griffith</surname> <given-names>M</given-names></string-name>, <string-name><surname>Subramanian</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dees</surname> <given-names>ND</given-names></string-name>, <string-name><surname>Kanchi</surname> <given-names>KL</given-names></string-name>, <etal>et al.</etal> <article-title>Genomic landscape of non-small cell lung cancer in smokers and never-smokers</article-title>. <source>Cell</source>. <year>2012</year>; <volume>150</volume>:<fpage>1121</fpage>&#x2013;<lpage>34</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Tumeh</surname> <given-names>PC</given-names></string-name>, <string-name><surname>Harview</surname> <given-names>CL</given-names></string-name>, <string-name><surname>Yearley</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Shintaku</surname> <given-names>IP</given-names></string-name>, <string-name><surname>Taylor</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Robert</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title>. <source>Nature</source>. <year>2014</year>; <volume>515</volume>:<fpage>568</fpage>&#x2013;<lpage>71</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Cha</surname> <given-names>E</given-names></string-name>, <string-name><surname>Klinger</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Cummings</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ribas</surname> <given-names>A</given-names></string-name>, <string-name><surname>Faham</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients</article-title>. <source>Science translational medicine</source>. <year>2014</year>; <volume>6</volume>:<fpage>238ra70</fpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Reuben</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gittelman</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>R</given-names></string-name>, <string-name><surname>Quek</surname> <given-names>K</given-names></string-name>, <string-name><surname>Vence</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>OA 13.05 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues</article-title>. <source>Journal of Thoracic Oncology</source>. <year>2017</year>; <volume>12</volume>:<fpage>S1780</fpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Gil Del Alcazar</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Ale&#x010D;kovi&#x0107;</surname> <given-names>M</given-names></string-name>, <string-name><surname>Polyak</surname> <given-names>K.</given-names></string-name> <article-title>Immune Escape during Breast Tumor Progression</article-title>. <source>Cancer immunology research</source>. <year>2020</year>; <volume>8</volume>:<fpage>422</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Walker</surname> <given-names>R</given-names></string-name>, <string-name><surname>Poleszczuk</surname> <given-names>J</given-names></string-name>, <string-name><surname>Pilon-Thomas</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>S</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>A</given-names></string-name>, <string-name><surname>Czerniecki</surname> <given-names>BJ</given-names></string-name>, <etal>et al.</etal> <article-title>Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy</article-title>. <source>Scientific reports</source>. <year>2018</year>; <volume>8</volume>:<fpage>9474</fpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Reuben</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gittelman</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Yusko</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>C-J</given-names></string-name>, <etal>et al.</etal> <article-title>TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence</article-title>. <source>Cancer discovery</source>. <year>2017</year>; <volume>7</volume>:<fpage>1088</fpage>&#x2013;<lpage>97</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Baras</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Drake</surname> <given-names>C</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>J-J</given-names></string-name>, <string-name><surname>Gandhi</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kates</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hoque</surname> <given-names>MO</given-names></string-name>, <etal>et al.</etal> <article-title>The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder</article-title>. <source>Oncoimmunology</source>. <year>2016</year>; <volume>5</volume>:<fpage>e1134412</fpage>&#x2013;<lpage>e</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Jordanova</surname> <given-names>ES</given-names></string-name>, <string-name><surname>Gorter</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ayachi</surname> <given-names>O</given-names></string-name>, <string-name><surname>Prins</surname> <given-names>F</given-names></string-name>, <string-name><surname>Durrant</surname> <given-names>LG</given-names></string-name>, <string-name><surname>Kenter</surname> <given-names>GG</given-names></string-name>, <etal>et al.</etal> <article-title>Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8&#x002B;/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?</article-title> <source>Clinical Cancer Research</source>. <year>2008</year>; <volume>14</volume>:<fpage>2028</fpage>&#x2013;<lpage>35</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Qi</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Glanville</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>JY</given-names></string-name>, <etal>et al.</etal> <article-title>Diversity and clonal selection in the human T-cell repertoire</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2014</year>; <volume>111</volume>:<fpage>13139</fpage>&#x2013;<lpage>44</lpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Labelle</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hynes</surname> <given-names>RO</given-names></string-name>. <article-title>The initial hours of metastasis: the importance of cooperative host&#x2013;tumor cell interactions during hematogenous dissemination</article-title>. <source>Cancer discovery</source>. <year>2012</year>; <volume>2</volume>:<fpage>1091</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Kitamura</surname> <given-names>T</given-names></string-name>, <string-name><surname>Qian</surname> <given-names>B-Z</given-names></string-name>, <string-name><surname>Pollard</surname> <given-names>JW</given-names></string-name>. <article-title>Immune cell promotion of metastasis</article-title>. <source>Nature Reviews Immunology</source>. <year>2015</year>; <volume>15</volume>:<fpage>73</fpage>&#x2013;<lpage>86</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Robert</surname> <given-names>L</given-names></string-name>, <string-name><surname>Tsoi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Emerson</surname> <given-names>R</given-names></string-name>, <string-name><surname>Homet</surname> <given-names>B</given-names></string-name>, <string-name><surname>Chodon</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>CTLA4 blockade broadens the peripheral T-cell receptor repertoire</article-title>. <source>Clinical cancer research : an official journal of the American Association for Cancer Research</source>. <year>2014</year>; <volume>20</volume>:<fpage>2424</fpage>&#x2013;<lpage>32</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Reuben</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gittelman</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Quek</surname> <given-names>K</given-names></string-name>, <string-name><surname>Vence</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Behrens</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Association of the T-cell receptor landscape with survival in non-small cell lung cancer</article-title>. <source>Journal of Clinical Oncology</source>. <year>2018</year>; <volume>36</volume>:<fpage>140</fpage>-.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Chiou</surname> <given-names>S-H</given-names></string-name>, <string-name><surname>Tseng</surname> <given-names>D</given-names></string-name>, <string-name><surname>Reuben</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mallajosyula</surname> <given-names>V</given-names></string-name>, <string-name><surname>Molina</surname> <given-names>IS</given-names></string-name>, <string-name><surname>Conley</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery</article-title>. <source>Immunity</source>. <year>2021</year>; <volume>54</volume>:<fpage>586</fpage>&#x2013;<lpage>602</lpage>. e8.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Reuben</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chiou</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Gittelman</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Li</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>WC</given-names></string-name>, <etal>et al.</etal> <article-title>Comprehensive T cell repertoire characterization of non-small cell lung cancer</article-title>. <source>Nat Commun</source>. <year>2020</year>; <volume>11</volume>:<fpage>603</fpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Simoni</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Becht</surname> <given-names>E</given-names></string-name>, <string-name><surname>Fehlings</surname> <given-names>M</given-names></string-name>, <string-name><surname>Loh</surname> <given-names>CY</given-names></string-name>, <string-name><surname>Koo</surname> <given-names>S-L</given-names></string-name>, <string-name><surname>Teng</surname> <given-names>KWW</given-names></string-name>, <etal>et al.</etal> <article-title>Bystander CD8&#x002B; T cells are abundant and phenotypically distinct in human tumour infiltrates</article-title>. <source>Nature</source>. <year>2018</year>; <volume>557</volume>:<fpage>575</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Scheper</surname> <given-names>W</given-names></string-name>, <string-name><surname>Kelderman</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fanchi</surname> <given-names>LF</given-names></string-name>, <string-name><surname>Linnemann</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bendle</surname> <given-names>G</given-names></string-name>, <string-name><surname>de Rooij</surname> <given-names>MA</given-names></string-name>, <etal>et al.</etal> <article-title>Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers</article-title>. <source>Nature medicine</source>. <year>2019</year>; <volume>25</volume>:<fpage>89</fpage>&#x2013;<lpage>94</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Fujimoto</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wedge</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Song</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing</article-title>. <source>Science</source>. <year>2014</year>; <volume>346</volume>:<fpage>256</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Reuben</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gittelman</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Yusko</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>CJ</given-names></string-name>, <etal>et al.</etal> <article-title>TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence</article-title>. <source>Cancer Discov</source>. <year>2017</year>; <volume>7</volume>:<fpage>1088</fpage>&#x2013;<lpage>97</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Lee</surname> <given-names>WC</given-names></string-name>, <string-name><surname>Reuben</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>X</given-names></string-name>, <string-name><surname>McGranahan</surname> <given-names>N</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>R</given-names></string-name>, <string-name><surname>Jalali</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity</article-title>. <source>Genome Biol</source>. <year>2020</year>; <volume>21</volume>:<fpage>271</fpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Hong</surname> <given-names>L</given-names></string-name>, <string-name><surname>Negrao</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Dibaj</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>R</given-names></string-name>, <string-name><surname>Reuben</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bohac</surname> <given-names>JM</given-names></string-name>, <etal>et al.</etal> <article-title>Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC</article-title>. <source>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</source>. <year>2020</year>; <volume>15</volume>:<fpage>1449</fpage>&#x2013;<lpage>59</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Li</surname> <given-names>L</given-names></string-name>, <string-name><surname>Yin</surname> <given-names>G</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>Genomic heterogeneity of multiple synchronous lung cancer</article-title>. <source>Nature communications</source>. <year>2016</year>; <volume>7</volume>:<fpage>1</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname> <given-names>R</given-names></string-name>, <string-name><surname>Keam</surname> <given-names>B</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>JW</given-names></string-name>, <etal>et al.</etal> <article-title>Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors</article-title>. <source>BMC cancer</source>. <year>2019</year>; <volume>19</volume>:<fpage>1</fpage>&#x2013;<lpage>10</lpage>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Vignot</surname> <given-names>S</given-names></string-name>, <string-name><surname>Frampton</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Soria</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Yelensky</surname> <given-names>R</given-names></string-name>, <string-name><surname>Commo</surname> <given-names>F</given-names></string-name>, <string-name><surname>Brambilla</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer</article-title>. <source>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</source>. <year>2013</year>; <volume>31</volume>:<fpage>2167</fpage>&#x2013;<lpage>72</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Fujimoto</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wedge</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Song</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing</article-title>. <source>Science (New York, NY)</source>. <year>2014</year>; <volume>346</volume>:<fpage>256</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Leong</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Gayevskiy</surname> <given-names>V</given-names></string-name>, <string-name><surname>Steinfort</surname> <given-names>DP</given-names></string-name>, <string-name><surname>De Massy</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Gonzalez-Rajal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Marini</surname> <given-names>KD</given-names></string-name>, <etal>et al.</etal> <article-title>Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer</article-title>. <source>Oncogene</source>. <year>2019</year>; <volume>38</volume>:<fpage>1661</fpage>&#x2013;<lpage>75</lpage>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Cheung</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Ewald</surname> <given-names>AJ</given-names></string-name>. <article-title>A collective route to metastasis: Seeding by tumor cell clusters</article-title>. <source>Science</source>. <year>2016</year>; <volume>352</volume>:<fpage>167</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Heyde</surname> <given-names>A</given-names></string-name>, <string-name><surname>Reiter</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Naxerova</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nowak</surname> <given-names>MA</given-names></string-name>. <article-title>Consecutive seeding and transfer of genetic diversity in metastasis</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>2019</year>; <volume>116</volume>:<fpage>14129</fpage>&#x2013;<lpage>37</lpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Reuben</surname> <given-names>A</given-names></string-name>, <string-name><surname>Spencer</surname> <given-names>CN</given-names></string-name>, <string-name><surname>Prieto</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Gopalakrishnan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Reddy</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>JP</given-names></string-name>, <etal>et al.</etal> <article-title>Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma</article-title>. <source>NPJ Genom Med</source>. <year>2017</year>; <volume>2</volume>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Becerra</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Reznik</surname> <given-names>E</given-names></string-name>, <string-name><surname>Redzematovic</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tennenbaum</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Kashan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ghanaat</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Comparative genomic profiling of matched primary and metastatic tumors in renal cell carcinoma</article-title>. <source>European urology focus</source>. <year>2018</year>; <volume>4</volume>:<fpage>986</fpage>&#x2013;<lpage>94</lpage>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Lim</surname> <given-names>B</given-names></string-name>, <string-name><surname>Mun</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Roh</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Cho</surname> <given-names>DH</given-names></string-name>, <etal>et al.</etal> <article-title>Genome-wide mutation profiles of colorectal tumors and associated liver metastases at the exome and transcriptome levels</article-title>. <source>Oncotarget</source>. <year>2015</year>; <volume>6</volume>:<fpage>22179</fpage>&#x2013;<lpage>90</lpage>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Ehrlich</surname> <given-names>M.</given-names></string-name> <article-title>DNA hypomethylation in cancer cells</article-title>. <source>Epigenomics</source>. <year>2009</year>; <volume>1</volume>:<fpage>239</fpage>&#x2013;<lpage>59</lpage>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Park</surname> <given-names>C</given-names></string-name>, <string-name><surname>Jeong</surname> <given-names>K</given-names></string-name>, <string-name><surname>Park</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Jung</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bae</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy</article-title>. <source>Cancer immunology, immunotherapy : CII</source>. <year>2021</year>; <volume>70</volume>:<fpage>1605</fpage>&#x2013;<lpage>17</lpage>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Rosenthal</surname> <given-names>R</given-names></string-name>, <string-name><surname>Cadieux</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Salgado</surname> <given-names>R</given-names></string-name>, <string-name><surname>Al Bakir</surname> <given-names>M</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Hiley</surname> <given-names>CT</given-names></string-name>, <etal>et al.</etal> <article-title>Neoantigen-directed immune escape in lung cancer evolution</article-title>. <source>Nature</source>. <year>2019</year>; <volume>567</volume>:<fpage>479</fpage>&#x2013;<lpage>85</lpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>AS</given-names></string-name>. <article-title>Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy</article-title>. <source>The Journal of pathology</source>. <year>2017</year>; <volume>241</volume>:<fpage>10</fpage>&#x2013;<lpage>24</lpage>.</mixed-citation></ref>
</ref-list>
<sec id="s6">
<title>Declarations</title>
<sec id="s6a">
<title>Ethics approval</title>
<p>Collection and use of patient samples were approved by the Institutional Review Board of the University of Texas MD Anderson Cancer Center.</p>
</sec>
<sec id="s6b">
<title>Consent for publication</title>
<p>Not applicable</p>
</sec>
<sec id="s6c">
<title>Competing interests</title>
<p>L.A.B. serves on advisory committees for AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar SA, Sierra Oncology, Merck, Bristol Myers Squibb, Genentech, and Pfizer and has research support from AbbVie, AstraZeneca, GenMab, Sierra Oncology and Tolero Pharmaceuticals. I.W. reports grants and personal fees from Genentech/Roche, Bayer, Bristol-Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Merck, and Guardant Health; personal fees from GlaxoSmithKline and MSD; grants from Oncoplex, DepArray, Adaptive, Adaptimmune, EMD Serono, Takeda, Amgen, Karus, Johnson &#x0026; Johnson, Iovance, 4D, Novartis, Oncocyte and Akoya. J.J.Z. reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed and Innovent outside the submitted work. J.V.H. reports honorariums from AstraZeneca, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche and Leads Biolabs. A.R. serves on the Scientific Advisory Board and has received honoraria from Adaptive Biotechnologies. The other authors declare no competing interests.</p>
</sec>
<sec id="s6d">
<title>Author contributions</title>
<p>A.R., D.L.G., L.A.B. and J.J.Z. conceived the study. J.L. and R.C. led the data analysis. J.F, D.T., and C.W.C. led the pathological assessment, multi-region sample preparation and DNA extraction. R.C., K.Q. and M.T. collected resected specimens and clinical data. L.L. and C.G. performed DNA preparation and whole-exome sequencing. X.S. and J.H.Z. performed sequencing raw data processing. J.L., X.H., K.Q., M.T. and A.M. performed downstream bioinformatics analyses. R.C., C.B, P.J., J.V.H., I.W., P.A.F., D.L.G, L.A.B., J.J.Z. and A.R. interpreted the data for clinical and pathological correlation. R.C. and J.L. performed statistical analyses. R.C., J.J.Z and A.R. wrote the paper. All authors edited the manuscript.</p>
</sec>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by Conquer Cancer Foundation ASCO Young Investigator Award, MD Anderson Physician Scientist Award, Cancer Prevention &#x0026; Research Institute of Texas (CPRIT) Multiple Investigator Award, TJ Martell Foundation, NIH/NCI R01-CA207295, NIH/NCI U01-CA213273 and Department of Defense (LC170171). A.R. is supported by the Exon 20 Group, Rexanna&#x2019;s Foundation for Fighting Lung Cancer, the Waun Ki Hong Lung Cancer Research Fund, MD Anderson&#x2019;s Lung Cancer Moon Shot and the University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer Center.</p>
</ack>
</back>
</article>